FDA chief: Woodcock is a 'change agent'

No, says Andrew von Eschenbach, it's not business-as-usual at the FDA. A thousand times no. The agency commish got peeved during an appearance at the American Enterprise Institute when someone suggested that appointing Janet Woodcock (photo) to her former post at the top of CDER was a return to the "old ways" at the agency. Au contraire, he said. She's "going back as a very, very strong change agent," he responded.

Is von Eschenbach worried that folks inside the FDA are misinterpreting his choice of Woodcock? He told the audience at AEI that he'd been "emphatic" about explaining his view on Woodcock's role: that she will create a CDER "nothing like the CDER that she left." He may also, In Vivo points out, be worried about his legacy at the agency. And he could be sensitive to charges that Woodcock can't be much of a change agent if she's a lame duck with only a few months to serve before a new president might bring in his or her own people into the FDA. Or maybe he saw the question a veiled criticism of his own leadership. Which, given all the fires FDA is trying to put out these days, might be understandable.

- see the item at In Vivo

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.